Ivan Luptak is a Cardiology physician affiliated with Boston University. OpenAlex indexes 76 publications with 3,082 citations (h-index 28).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
732 Harrison Ave
Preston 3rd Floor
Boston, MA 021182309
Telephone
617-638-7490Provider last certified this registry record 27 Dec 2019.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
73.8%Beta blocker17.5%Metoprolol Succinate71%Carvedilol29%Part D<11 patientsLoop diuretic11.6%Furosemide75%Torsemide26%Part D<11 patients+ 6 more classes in this area
Metabolism & gastrointestinal
26.2%SGLT2 inhibitor26.2%Jardiance84%Farxiga16%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2022–2026 per NIH RePORTER. The latest:
- Targeting Energetics to Improve Outcomes in Hypertrophic Cardiomyopathy
Boston Medical Center
FY2026$770,364R01HL166606 - Targeting Energetics to Improve Outcomes in Hypertrophic Cardiomyopathy
Boston Medical Center
FY2025$796,064R01HL166606 - Targeting Energetics to Improve Outcomes in Hypertrophic Cardiomyopathy
Boston Medical Center
FY2024$833,881R01HL166606
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- SGLT2 inhibitor upregulates myocardial genes for oxidative phosphorylation and fatty acid metabolism in Gαq-mice
Journal of Molecular and Cellular Cardiology Plus
2025 - Do weight loss interventions challenge the obesity paradox in heart failure?
Trends in Endocrinology and Metabolism
2025 - Multi-Omics Profiling of Hypertrophic Cardiomyopathy Reveals Altered Mechanisms in Mitochondrial Dynamics and Excitation–Contraction Coupling
International Journal of Molecular Sciences
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Holick, MD
Boston University
Gene Kwan, MD
Boston University
Joseph Antin, MD
Boston University
George O'Connor, MD
Boston University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”